Sept. 11, 2024 |
|
Sept. 11, 2024 |
|
jRCT2071240056 |
ONO-4915-01:ONO-4915 Phase I study |
|
ONO-4915-01:ONO-4915 Phase I study |
Hirashima Yoshinori |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
||
Medical Information Center |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
Recruiting |
Sept. 11, 2024 |
||
160 | ||
Interventional |
||
randomized controlled trial |
||
single blind |
||
placebo control |
||
parallel assignment |
||
treatment purpose |
||
1) Japanese healthy adult male subjects |
||
1) Subjects who are on a treatment for or with a history of respiratory, cardiovascular, psychiatric, neurologic, gastrointestinal, immunologic, hepatic, renal, hematopoietic or endocrine and/or other disease. |
||
18age old over | ||
45age old under | ||
Male |
||
Auto immune disease |
||
1) Single intravenous infusion part |
||
Safety, Pharmacokinetics |
||
Pharmacodynamics,Immunogenicity |
Ono Pharmaceutical Co.,LTD |
Hakata Clinic Institutional Review Board | |
6-18, Tenyamachi, Hakata-ku, Fukuoka, Japan, Fukuoka | |
+81-92-283-7701 |
|
miyako-koga@lta-med.com | |
Not approval | |
No |
|
none |